Want to see PBH full AI Analyst Report?

Prestige Consumer Healthcare (PBH) Earnings Dates, Call Summary & Reports

123 Followers

Earnings Data

Report Date

Jul 30, 2026

Before Open (Confirmed)

Period Ending

2027 (Q1)

Consensus EPS Forecast

0.88

Last Year’s EPS

0.95

Same Quarter Last Year

Analyst Consensus

Moderate Buy

Based on 3 Analysts Ratings

Earnings Call Summary

Q4 2026

Earnings Call Date:May 13, 2026|

% Change Since:

Earnings Call Sentiment|Neutral

Balanced: the call highlighted strong cash generation, margin resilience, strategic M&A (Pillar5, Breathe Right, LaCorium) and digital/channel strengths (e‑commerce ~18%), which position the company for medium‑term upside. However, significant near‑term execution risks—chiefly Clear Eyes supply disruptions, production ramp uncertainty, and shipping disruptions from geopolitical events—drove fiscal '26 revenue declines and create short‑term volatility. Management provided cautious fiscal '27 guidance that assumes improvement in the back half of the year and emphasized deleveraging after acquisitions.

Company Guidance

For fiscal 2027 Prestige is guiding to revenues of $1.10–$1.12 billion with organic growth of roughly 1–3%, adjusted EPS of $4.42–$4.51, and Q1 revenue of about $250 million with Q1 adjusted EPS of ~$0.87; adjusted gross margin is expected to be roughly flat to FY26 (FY26: 55.6%), advertising & marketing above 13% of sales (FY26: 13.7%), adjusted G&A about 10.5% of sales with Q1 G&A ~ $30 million, CapEx ~ $25 million, and free cash flow of $250 million or more (FY26 FCF $246.4 million). The balance sheet at March 31 showed net debt of ~ $900 million and covenant leverage of 2.6x; management expects cumulative cash flow over the next three years (including pending acquisitions) to approach $900 million, intends to deleverage toward ~3x after closing Breathe Right and LaCorium, and retains >$90 million of share‑repurchase authorization (after >$150 million repurchased in FY26). Pending deals: Breathe Right ~>$125 million of revenue and was previously estimated to be ~+$0.25 EPS (annualized) and LaCorium ~>$40 million of revenue with ~ $12 million run‑rate EBITDA when fully integrated. Guidance embeds continued oil‑related inflation and diesel cost pressure to be offset by cost actions and tactical pricing; management expects eye care production to meaningfully ramp in the back half of FY27, sees a path to a ~10% revenue CAGR through FY29 (organic long‑term 2–3%), low‑to‑mid‑30s EBITDA margins, and an EPS CAGR of ~8%+ to FY29.

Strong Free Cash Flow Generation

Generated $246.4M in free cash flow for fiscal '26, up ~1.3% year-over-year; company expects >= $250M in free cash flow for fiscal '27 and projects cumulative cash flow approaching $900M over the next 3 years (preliminary, excluding pending acquisitions).

Disciplined Capital Allocation and Shareholder Returns

Returned capital via >$150M in share repurchases in fiscal '26 and invested ~$110M in Pillar5 to secure eye care manufacturing; $90M+ of repurchase authorization remains; prioritizing brand investment, debt reduction, and M&A.

Margins and Profitability Resilience

Adjusted gross margin was 55.6% for fiscal '26, essentially flat versus prior year (55.8%); company maintained a low-30s EBITDA margin profile despite sales headwinds.

Completed and Announced Strategic Acquisitions

Acquired Pillar5 (Dec) to internalize eye care production; announced pending acquisitions of Breathe Right (expected >$125M revenue) and LaCorium (~$40M revenue). Breathe Right previously estimated to be ~+$0.25 EPS (annualized) and LaCorium expected to be neutral-to-slightly-accretive on close.

E-commerce and Brand Strength

E-commerce penetration reached ~18% with continued double-digit consumption growth; leading franchise performance highlighted (Fleet >50% market share; GI brands grew; Summer's Eve stabilized; Monistat held share despite category declines).

FY'27 Initial Guidance

Management guided fiscal '27 revenue $1.10B–$1.12B with organic growth ~1%–3%, adjusted EPS $4.42–$4.51, Q1 revenue ~ $250M and EPS ~$0.87, and gross margin expected roughly in line with fiscal '26.

Low Capital Expenditure Profile

Corporate model supports low capex (~1%–3% of sales); management expects ~ $25M capex for fiscal '27 even including Pillar5, preserving strong free cash flow conversion.

Medium-Term Growth Targets

Management expects catalysts (acquisitions + eye care recovery + international expansion) to target revenue CAGR approaching ~10% through fiscal '29 and EPS CAGR of ~8%+, with international footprint potentially approaching ~20% of sales.

Prestige Consumer Healthcare (PBH) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

PBH Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Jul 30, 2026	2027 (Q1)	0.88 / -	0.95	―	―	―
May 13, 2026	2026 (Q4)	1.39 / 1.23	1.32	-6.82% (-0.09)
Feb 05, 2026	2026 (Q3)	1.15 / 1.14	1.22	-6.56% (-0.08)
Nov 06, 2025	2026 (Q2)	0.97 / 1.07	1.09	-1.83% (-0.02)
Aug 07, 2025	2026 (Q1)	1.00 / 0.95	0.9	5.56% (+0.05)
May 08, 2025	2025 (Q4)	1.30 / 1.32	1.02	29.41% (+0.30)
Feb 06, 2025	2025 (Q3)	1.18 / 1.22	1.06	15.09% (+0.16)
Nov 07, 2024	2025 (Q2)	1.08 / 1.09	1.07	1.87% (+0.02)
Aug 08, 2024	2025 (Q1)	0.86 / 0.90	1.06	-15.09% (-0.16)
May 14, 2024	2024 (Q4)	1.14 / 1.02	1.07	-4.67% (-0.05)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

PBH Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 13, 2026	$51.81	$45.93	-11.35%
Feb 05, 2026	$67.03	$65.55	-2.21%
Nov 06, 2025	$59.83	$61.36	+2.56%
Aug 07, 2025	$75.16	$67.61	-10.05%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Prestige Consumer Healthcare (PBH) report earnings?

Prestige Consumer Healthcare (PBH) is schdueled to report earning on Jul 30, 2026, Before Open (Confirmed).

What is Prestige Consumer Healthcare (PBH) earnings time?

Prestige Consumer Healthcare (PBH) earnings time is at Jul 30, 2026, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is PBH EPS forecast?

PBH EPS forecast for the fiscal quarter 2027 (Q1) is 0.88.